Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2012-04-30EMA Application withdrawn: Pioglitazone ratiopharm GmbH (pioglitazone) — Ratiopharm GmbH
The EMA withdrew the application for pioglitazone (Ratiopharm GmbH) for type 2 diabetes.
-
EMA withdrawal · 2012-04-30EMA Application withdrawn: Pioglitazone ratio (pioglitazone) — Ratiopharm GmbH
The EMA has withdrawn an application for a pioglitazone ratio product by Ratiopharm GmbH, related to Type 2 diabetes.
-
CLINICAL_TRIALS withdrawal · 2012-02-22Clinical Trial Update: Telephone Intervention in Patients With Acute Coronary Syndrome (ACS) and Diabetes [NA]
A clinical trial evaluating a telephone intervention for patients with acute coronary syndrome and type 2 diabetes was terminated.
-
CLINICAL_TRIALS withdrawal · 2011-09-21Clinical Trial Update: Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone [Phase 3]
A Phase 3 trial evaluating dutogliptin in Type 2 diabetes patients receiving background glimepiride, with or without metformin or pioglitazo…
-
CLINICAL_TRIALS withdrawal · 2011-08-25Clinical Trial Update: A Study in Patients With Type 2 Diabetes [Phase 2]
A Phase 2 clinical trial conducted by Eli Lilly in patients with Type 2 diabetes mellitus has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2011-08-12EMA Withdrawn: Avaglim (rosiglitazone;glimepiride) — SmithKline Beecham Ltd
Avaglim (rosiglitazone; glimepiride) has been withdrawn from the market.
-
CLINICAL_TRIALS withdrawal · 2010-12-10Clinical Trial Update: Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors [Phase 3]
A Phase 3 trial evaluating the impact of rimonabant on regression of asymptomatic cardiovascular damage was terminated.
-
CLINICAL_TRIALS withdrawal · 2010-08-17Clinical Trial Update: Genetic Variation in OCT1 and Response to Metformin [Phase 4]
A Phase 4 clinical trial examining the influence of OCT1 genetic variation on metformin response in Type 2 Diabetes was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2010-07-23Clinical Trial Update: Treatment of Type 2 Diabetes Mellitus by Duodenal Exclusion Associated With Omentectomy: Clinical and Hormonal Study [Phase 1, Phase 2]
A Phase 1/2 trial investigating duodenal exclusion with omentectomy for type 2 diabetes mellitus was terminated, with no results reported in…
-
EMA withdrawal · 2010-05-15EMA Application withdrawn: Repaglinide Sun (repaglinide) — Sun Pharmaceutical Industries B.V.
The EMA withdrew the application for Repaglinide Sun for type 2 diabetes.
-
EMA withdrawal · 2009-08-24EMA Lapsed: Trazec (nateglinide) — Novartis Europharm Ltd.
The EMA page indicates that Trazec (nateglinide) has a lapsed status and is no longer active in the market.
-
CLINICAL_TRIALS withdrawal · 2008-01-09Clinical Trial Update: BMS-646256 in Obese and Overweight Type 2 Diabetics [Phase 2, Phase 3]
A Phase 2/Phase 3 trial of BMS-646256 in obese and overweight adults with Type 2 diabetes was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2007-08-21Clinical Trial Update: Inflammatory Response and Pregnancy Outcome in Women With Type 2 Diabetes or Overweight [Phase 1]
A Phase 1 trial investigating inflammatory response and pregnancy outcomes in women with type 2 diabetes mellitus or overweight has been wit…
-
EMA withdrawal · 2006-12-08EMA Application withdrawn: Synordia (fenofibrate;metformin) — Fournier Laboratories Ireland Ltd.
The EMA withdrew the application for Synordia (fenofibrate; metformin) from Fournier Laboratories Ireland Ltd. for Diabetes Type 2.
-
CLINICAL_TRIALS withdrawal · 2006-09-08Clinical Trial Update: Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina [Phase 4]
A Phase 4 trial comparing rosiglitazone versus gliclazide in adults with type 2 diabetes and angina has been withdrawn.